CVE-2026-56694: nanocoai nanoclaw · Incorrect Authorization
Affects nanocoai nanoclawSource CVE Database V5
Not known to be exploited · CVSS 5.3 Medium : upgrade to 2.1.0 when convenient.
Data as of 5 Nov 2026, 23:24 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 22% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
- Patch
- Available – fixed in 2.1.0
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:NExploitation evidence
Disclosed: evidence found.
CVE published 23 Jun 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 5 Nov 2026.
What to do
Upgrade nanocoai nanoclaw to 2.1.0.
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| nanocoainanoclaw | Affected
| Fixed in
|
GitHubnanoclawpkg:github/nanoclawOther threats | Affected
| Fixed in
|
Check your own hosts for these packages with threat-finder (opens in a new tab), our free open-source scanner.
AI-suggested
If you cannot patch yet, restrict admin privileges carefully and audit channel registration activities to detect potential misuse.
Description
NanoClaw before 2.1.0 contains a privilege escalation vulnerability in the channel-registration approval flow where handleChannelApprovalResponse fails to validate admin privileges over target agent groups. Scoped admins can submit forged or stale connect callback values to wire messaging channels into out-of-scope agent groups, exposing unauthorized groups to unapproved channels and enabling unauthorized observation or control of restricted agent group activity.